Table 2. Pathologic variables in patients undergoing preoperative chemotherapy±radiation therapy for gastric and gastrooesophageal junction adenocarcinoma, followed by R0 resection.

	Number (%)
Variable	Non-pCR patients (n=549)	pCR patients (n=60)	P-value
pT stage a
T0b	11 (2)	60 (100)
T1a	21 (4)	0
T1b	48 (9)	0
T2	125 (23)	0	N/A
T3	243 (44)	0
T4a	93 (17)	0
T4b	8 (1)	0
pN stage a
N0	241 (44)	60 (100)
N1	131 (24)	0
N2	97 (18)	0	N/A
N3a	59 (11)	0
N3b	21 (4)	0
Extent of surgical lymphadenectomy
D1	20 (4)	1 (2)
D2	513 (93)	57 (95)	0.72c
D3	16 (3)	2 (3)
Number of positive LN (for ⩾N1; mean, IQR)	3.0 (1–8)	0 (0)	N/A
Number of LN examined (mean, IQR)	23 (15–29)	29 (25–32)	0.04d
Pathologic treatment effect (mean %, IQR)	45 (10–95)	100	N/A

Abbreviations: IQR=interquartile range; LN=lymph node; N/A=not applicable (no statistical analysis performed, as differences are defined by subgroup stratification); pCR=pathologic complete response.

^aAJCC 7th edn, 2010.

^bT0N1 (n=9) and T0N2 (n=2) – 1 patient has recurred after a median follow-up of 17 months.

^cχ² text.

^dWilcoxon rank sum test with continuity correction. Bold values indicate significant differences.